Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
2600 Kelly Road
Warrington
Pennsylvania
18976
United States
Tel: 215-488-9300
Fax: 215-488-9301
Website: http://www.discoverylabs.com/
409 articles about Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
-
Discovery Laboratories Reports Fourth Quarter 2009 Financial Results and Provides Business Update
3/10/2010
-
Discovery Laboratories Announces Completion of $16.5 Million Public Offering
2/23/2010
-
Discovery Laboratories Prices $16.5 Million Public Offering of Common Stock and Warrants
2/18/2010
-
Discovery Laboratories Receives Nasdaq Notification Related to Minimum Bid Price
12/7/2009
-
Discovery Laboratories Submits SURFAXIN Pharmacodynamic Trial Protocol to FDA
11/17/2009
-
Discovery Laboratories to Present at the Lazard Capital Markets Healthcare Conference
11/11/2009
-
Discovery Laboratories Says to Look for Pipeline Funding
11/5/2009
-
Discovery Laboratories' Third Quarter 2009 Financial Update
11/4/2009
-
Discovery Laboratories Provides Business and Pipeline Development Update
11/4/2009
-
Discovery Laboratories Schedules Conference Call and Webcast
11/2/2009
-
Discovery Laboratories Says FDA Agrees on Lung Drug Program
9/30/2009
-
Discovery Laboratories to Meet FDA to Review Lung Drug Options
9/11/2009
-
Discovery Laboratories Announces Date of 2009 Annual Shareholder Meeting
9/8/2009
-
Discovery Laboratories CEO Resigns
8/14/2009
-
Discovery Laboratories Assessing Strategic, Financial Options
7/30/2009
-
Discovery Laboratories and FDA to Meet On June 2, 2009 to Discuss SURFAXIN Complete Response Letter
5/12/2009
-
Discovery Laboratories to Raise $11.3 Million in Registered Direct Offering
5/11/2009
-
Discovery Laboratories' Surfaxin(r) Significantly Improves Lung Surfactant Distribution in Preclinical RDS Model
5/5/2009
-
Discovery Laboratories' KL4 Surfactant Shows Physiologic and Survival Benefit in a Preclinical Model for Severe Respiratory Condition -- Acute Lung Injury
5/4/2009
-
Discovery Laboratories Receives Notice of Allowance for Patent to Treat Infants At Risk of Developing Bronchopulmonary Dysplasia
5/1/2009